Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy - PubMed (original) (raw)
Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy
G M Boxer et al. Br J Cancer. 1994 Feb.
Free PMC article
Abstract
Antibody targeting has potential for selective delivery of cancer therapy. However, there is a wide variation in the degree of antibody localisation in individual patients with colorectal adenocarcinoma. Colorectal adenocarcinomas are composed of glandular structures separated from fibrovascular stroma by a basal lamina which may represent a significant barrier to extravasated antibody. Basement membrane-associated CEA epitopes may be more accessible to antibodies than those which are cytoplasmic or lumenal. We have investigated by immunohistochemistry and in vivo localisation, the extent to which distribution of antigen epitopes influences targeting. Two monoclonal antibodies (A5B7 and EA77) recognising non-overlapping CEA epitopes were reacted immunohistochemically with samples of 39 tumours. Intensity and site of reaction were assessed for basement membrane, cytoplasmic or lumenal surface association. 125I-labelled antibodies were injected into nude mice bearing LS174T tumour. Per cent injected activity per gram was measured in tumour and normal tissues, 24, 72 and 168 h later. Tissues reacted immunohistochemically for CEA were autoradiographed to assess the relationship of injected antibody to target antigen. Immunohistochemistry showed that A5B7 antibody favours basement membrane aspects of malignant glands; in contrast, EA77 concentrated generally on lumenal surfaces. In vivo localisation showed that per cent inj.act g-1 in tumour for A5B7 reached 36.5% at 24 h. EA77 localised to a lesser extent (9.1% at 24 h), despite a longer circulatory half-life. Autoradiography combined with immunohistochemistry showed A5B7 reacting with antigen close to vasculature after 24 h, slowly penetrating deeper parts of the tumour by 72 h. In contrast, EA77 was confined mainly to fibrovascular stroma, showing little labelling of antigen-positive tumour cells. Localisation differences between A5B7 and EA77 may partly be due to accessibility of epitopes on tumour cells.
Similar articles
- Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.
Boxer GM, Begent RH, Kelly AM, Southall PJ, Blair SB, Theodorou NA, Dawson PM, Ledermann JA. Boxer GM, et al. Br J Cancer. 1992 Jun;65(6):825-31. doi: 10.1038/bjc.1992.176. Br J Cancer. 1992. PMID: 1616854 Free PMC article. - A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma.
Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. Rajkumar VS, et al. Tumour Biol. 2012 Dec;33(6):2019-29. doi: 10.1007/s13277-012-0461-9. Epub 2012 Jul 26. Tumour Biol. 2012. PMID: 22833213 - Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M, Garambois V, Pourquier D, Gutowski M, Rouanet P, Mani JC, Pugnière M, Hynes NE, Pèlegrin A. Dorvillius M, et al. Tumour Biol. 2002 Nov-Dec;23(6):337-47. doi: 10.1159/000069793. Tumour Biol. 2002. PMID: 12677091 - Limitations associated with the use of labelled antibodies against CEA for potential tumour localisation and therapy. A review.
Rogers GT. Rogers GT. Eur J Cancer Clin Oncol. 1986 Oct;22(10):1127-33. doi: 10.1016/0277-5379(86)90312-3. Eur J Cancer Clin Oncol. 1986. PMID: 3545850 Review. No abstract available. - Carcinoembryonic antigen: a rat model.
Abeyounis CJ, Kim JG, Wilhelm SA, Diakun KR, Milgrom F. Abeyounis CJ, et al. Immunol Invest. 1989 Jan-May;18(1-4):143-57. doi: 10.3109/08820138909112234. Immunol Invest. 1989. PMID: 2471689 Review.
Cited by
- Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer.
Ornadel D, Ledermann JA, Eagle K, Pedley RB, Boxer G, Ward SE, Olabiran Y, Bomanji J. Ornadel D, et al. Br J Cancer. 1998;77(1):103-9. doi: 10.1038/bjc.1998.16. Br J Cancer. 1998. PMID: 9459153 Free PMC article. - A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH. Francis RJ, et al. Br J Cancer. 2002 Sep 9;87(6):600-7. doi: 10.1038/sj.bjc.6600517. Br J Cancer. 2002. PMID: 12237768 Free PMC article. Clinical Trial. - The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
Pedley RB, Boden JA, Boden R, Begent RH, Turner A, Haines AM, King DJ. Pedley RB, et al. Br J Cancer. 1994 Dec;70(6):1126-30. doi: 10.1038/bjc.1994.459. Br J Cancer. 1994. PMID: 7981064 Free PMC article. - Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).
Antoniw P, Farnsworth AP, Turner A, Haines AM, Mountain A, Mackintosh J, Shochat D, Humm J, Welt S, Old LJ, Yarranton GT, King DJ. Antoniw P, et al. Br J Cancer. 1996 Aug;74(4):513-24. doi: 10.1038/bjc.1996.395. Br J Cancer. 1996. PMID: 8761364 Free PMC article. - The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, Dall'Acqua W, Damschroder M, Hammond SA. Peng L, et al. PLoS One. 2012;7(5):e36412. doi: 10.1371/journal.pone.0036412. Epub 2012 May 4. PLoS One. 2012. PMID: 22574157 Free PMC article.
References
- In Vitro. 1976 Mar;12(3):180-91 - PubMed
- Cancer. 1982 May 15;49(10):2077-90 - PubMed
- Int J Cancer. 1982 May 15;29(5):539-45 - PubMed
- J Natl Cancer Inst. 1989 Apr 19;81(8):570-6 - PubMed
- Br J Cancer. 1989 Sep;60(3):406-12 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical